권호기사보기
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
대표형(전거형, Authority) | 생물정보 | 이형(異形, Variant) | 소속 | 직위 | 직업 | 활동분야 | 주기 | 서지 | |
---|---|---|---|---|---|---|---|---|---|
연구/단체명을 입력해주세요. |
|
|
|
|
|
* 주제를 선택하시면 검색 상세로 이동합니다.
목차
중등증 및 중증 건선환자의 치료에서 Adalimumab, Ustekinumab, Secukinumab, Guselkumab의 안전성에 대한 국내연구 : 실제임상자료 기반한 단일기관 연구 = Safety of adalimumab, ustekinumab, secukinumab, guselkumab in korean patients with moderate to severe psoriasis : a real-world data in a single medical center / 정수현 ; 오동열 ; 박은주 ; 김광호 ; 김광중 1
[요약] 1
서론 1
대상 및 방법 2
1. 연구 대상 2
2. 조사 방법 2
3. 통계적 분석 2
결과 2
1. 인구 통계학적 정보 2
2. Adverse event 2
3. Efficacy of biologies 3
고찰 4
결론 6
REFERENCES 6
번호 | 참고문헌 | 국회도서관 소장유무 |
---|---|---|
1 | Kim KO, Lee SH, Lee SY, Whang KU, Park YL. Efficacy and safety of ustekinumab in Korean patients with moderate-to-severe psoriasis. Korean J Dermatol 2015;53:366-373 | 미소장 |
2 | Won SH, Shin K, Kim HS, Ko HC, Kim MB, Kim BS. Efficacy and safety of ixekizumab for the treatment of moderate to severe psoriasis in Korea. Korean J Dermatol 2020;58:389-396 | 미소장 |
3 | Ha DL, Kim WI, Yang MY, Lee WK, Kim T, Park S, et al. Efficacy and safety of secukinumab for the treatment of moderate to severe psoriasis in Korea. Korean J Dermatol 2019;57:9-14 | 미소장 |
4 | Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - comparison among therapeutic TNF-α antagonists. Cytokine 2018;101:56-63. doi: 10.1016/j.cyto.2016.08.014 | 미소장 |
5 | Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis 2018;9:147-158. doi: 10.1177/2040622318772705 | 미소장 |
6 | Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, et al. Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: a network meta-analysis. J Pharmacol Sci 2019;139:289-303. doi: 10.1016/j.jphs.2018.12.006 | 미소장 |
7 | Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol 2015;195:780-788. doi: 10.4049/jimmunol.1500909 | 미소장 |
8 | Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015;73:400-409. doi: 10.1016/j.jaad.2015.05.013 | 미소장 |
9 | Ryoo JY, Yang HJ, Ji E, Yoo BK. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann Pharmacother 2016;50:341-351. doi:10.1177/1060028015626545 | 미소장 |
10 | Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment - a metaanalysis of 43 studies. J Eur Acad Dermatol Venereol 2020;34:1174-1185. doi: 10.1111/jdv.16180 | 미소장 |
11 | Chiu HY, Hui RC, Huang YH, Huang RY, Chen KL, Tsai YC, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol 2018;98:829-834. doi: 10.2340/00015555-2989 | 미소장 |
12 | Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al.; Secukinumab in Crohn’s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease:unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-1700. doi: 10.1136/gutjnl-2011-301668 | 미소장 |
13 | Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019;78:473-479. doi: 10.1136/annrheumdis-2018-214273 | 미소장 |
14 | Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol 2020;34:533-541. doi: 10.1111/jdv.16004 | 미소장 |
15 | Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn’s disease: an integrated analysis of phase II/III clinical development programs. Drug Saf 2019;42:751-768. doi: 10.1007/s40264-019-00797-3 | 미소장 |
16 | Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context 2019;8:212594. doi: 10.7573/dic.212594 | 미소장 |
17 | Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019;394:831-839. doi: 10.1016/S0140-6736(19)31773-8 | 미소장 |
*표시는 필수 입력사항입니다.
*전화번호 | ※ '-' 없이 휴대폰번호를 입력하세요 |
---|
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
---|
도서위치안내: 정기간행물실(524호) / 서가번호: 국내03
2021년 이전 정기간행물은 온라인 신청(원문 구축 자료는 원문 이용)
우편복사 목록담기를 완료하였습니다.
*표시는 필수 입력사항입니다.
저장 되었습니다.